Fig. 1 · Structure

Documents & Downloads

Moclobemide

Cat. No. A11885 CAS 71320-77-9

MAO Inhibitor

Moclobemide is a reversible and selective inhibitor of monoamine oxidase A (MAO-A).

In Stock

Publications for Moclobemide

1 publication citing this product

  1. Linyu Cao, .et al. , Eur J Pharmacol, 2020, Jun 5;876:173058 PMID: 32131022

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Moclobemide inhibited recombinant MAO-A in a cell-free fluorometric assay, with a reported IC50 of 6.061 ± 0.262 µM (mean ± SD). This assay-specific potency is distinct from cellular exposure concentrations or animal treatment doses. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
MAO-A (5-HT) 6.1 μM

Cellular Effect

Cell Line Activity Value Description Reference
BTI-TN-5B1-4 IC50 361 μM Inhibition of human recombinant microsomal MAO-A expressed in baculovirus-infected insect BTI-TN-5B1-4 cells assessed as p-tyramine conversion to H2O2 by fluorescence assay [PMID: 23927971]
BTI-TN-5B1-4 IC50 361 μM Inhibition of human recombinant microsomal MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate assessed as reduction in H2O2 production preincubated for 15 mins followed by substrate addition measured for 15 mins Ample [PMID: 27135371]
BTI-TN-5B1-4 IC50 361 μM Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect sells assessed as hydrogen peroxide production by fluorimetric method [PMID: 21405131]
BTI-TN-5B1-4 IC50 361.38 nM Inhibition of human recombinant MAOA expressed in BTI-TN-5B1-4 cells using p-tyramine substrate assessed as reduction in H2O2 production [PMID: 25532905]
BTI-TN-5B1-4 IC50 361.38 μM Inhibition of human recombinant MAOA expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine after 15 mins by amplex red assay [PMID: 22005185]
BTI-TN-5B1-4 IC50 361.38 μM Inhibition of human MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells using p-tyramine as substrate incubated for 15 mins prior to substrate addition measured for 15 mins by Amplex red assay [PMID: 23153812]
BTI-TN-5B1-4 IC50 361.38 μM Inhibition of human recombinant MAOA expressed in baculovirus infected insect BTI-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine by amplex red assay [PMID: 20715818]
BTI-TN-5B1-4 IC50 361.38 μM Inhibition of human recombinant MAO-A expressed in baculovirus-infected BTI-TN-5B1-4 cell microsomes assessed as decrease in H2O2 production using p-tyramine as substrate preincubated for 15 mins by Amplex Red reagent based fluorimetric method [PMID: 24746464]
BTI-TN-5B1-4 IC50 361.38 μM Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as inhibition of hydrogen peroxide production from p-tryptamine after 15 mins by fluorimetric method [PMID: 22222137]
BTI-TN-5B1-4 IC50 361.38 μM Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as production of hydrogen peroxide from p-tyramine after 15 mins by microplate fluorescence assay [PMID: 21872365]
BTI-TN-5B1-4 IC50 361.38 μM Inhibition of human MAO-A expressed in baculovirus infected BTI-TN-5B1-4 insect cells using p-tyramine as substrate assessed as hydrogen peroxide production by fluorimetric method 10.1039/C0MD00014K
BTI-TN-5B1-4 IC50 361.38 μM Inhibition of human recombinant MAOA expressed in BTI-TN-5B1-4 cells by para-tyramine oxidation assay [PMID: 20045650]
BTI-TN-5B1-4 IC50 361.38 μM Inhibition of human recombinant MAOA expressed in BTI-TN-5B1-4 cells assessed as effect on H2O2 production from para-tyramine by fluorimetric method [PMID: 19267475]
BTI-TN-5B1-4 IC50 361382 nM Inhibition of human recombinant MAOA expressed in baculovirus infected BTI-TN-5B1-4 insect cells assessed as hydrogen peroxide production from p-tyramine by amplex red assay [PMID: 20579890]
SH-SY5Y IC50 > 100 μM Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 72 hrs by MTT assay [PMID: 28756263]

15 records · Scroll to view more

Moclobemide Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Moclobemide from 3 published references.

Moclobemide In Vitro Studies

In rat hippocampal neural stem-cell cultures, moclobemide increased the MTT viability signal at 50 µM, while concentrations above 75 µM reduced viability. At 400 µM, viability was 63.1±5.8%, 56.3±5.4% and 52.4±6.1% of control after 24, 48 and 72 h, respectively (mean ± SD). [2]

Moclobemide as an MAO-A assay reference

Biochemical assay · Recombinant MAO-A in a cell-free fluorometric assay using tyramine and Ampliflu Red/horseradish peroxidase. Species is not specified in Section 2.2. [1]

Moclobemide inhibited MAO-A with a reported IC50 of 6.061 ± 0.262 µM (mean ± SD). Blank, DMSO control, peroxidase-interference and non-enzymatic fluorescence checks are described. The paper’s competitive/reversible kinetic conclusion concerns compound 3e and is not assigned to moclobemide.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Half-maximal inhibition of recombinant MAO-AIC50 6.061 ± 0.262 µM (mean ± SD)[1]

Literature-Reported Treatment Conditions

Treatment concentration
10⁻³–10⁻⁹ M inhibitor solutions, as reported; this range is distinct from the fitted IC50.
Exposure duration
30 min inhibitor–enzyme preincubation at 37 °C; 30 min reaction at 37 °C with fluorescence measured at 5 min intervals.
Method
Cell-free enzyme inhibition assay with tyramine as substrate.
Vehicle
Inhibitor solutions prepared in 2% DMSO; vehicle controls replace inhibitor solution with the same 20 µL of 2% DMSO. This is not a claim of 2% final-well DMSO.
Reported limits
Moclobemide salt, lot/purity, enzyme species and independent assay-repeat count are not specified in the selected methods. No moclobemide MAO-B result is supplied in Table 2 (dash entries).
Methods and source locations

Compound reported in the paper: Moclobemide; Compound label in the paper: moclobemide

Evidence concerns the named compound and reported source material; it does not validate Adooq material, purity or a lot.

Section 2.2; Section 3.2; Tables 2–3, moclobemide rows

Half-maximal inhibition of recombinant MAO-A: Fluorescence Ex/Em 535/587 nm; inhibitor/blank/control concentrations analyzed in quadruplicate; dose-response fitting in GraphPad Prism 5.0. Independent repeat-assay count not specified. — Table 3, moclobemide IC50 column; Section 2.2

Concentration-dependent viability in rat neural stem cells

Cell-based study · Neural stem-cell cultures isolated from the hippocampus of adult Sprague–Dawley rats (8 weeks old, 250 g). [2]

In the tested concentration series, 50 µM moclobemide increased the MTT viability signal, whereas concentrations above 75 µM reduced viability. At 400 µM the reported signal fell at each tested time. Cell counts compared 50 and 200 µM with control. These are cultured-cell findings; MTT alone does not establish neurogenesis.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MTT signal relative to untreated control across tested exposure timesDirection of response Increased at 50 µM; Figure 1g caption marks P<0.05 versus control.[2]
MTT viability at 400 µM relative to no-MB controlPercent of control 24 h: 63.1±5.8%; 48 h: 56.3±5.4%; 72 h: 52.4±6.1%; P<0.01 for each (Results text).[2]

Literature-Reported Treatment Conditions

Treatment concentration
0, 10, 25, 50, 75, 100, 200 and 400 µM for MTT; 50 and 200 µM for the cell-count growth curve.
Exposure duration
24, 48 and 72 h.
Method
Exposure of rat hippocampal NSC cultures; MTT viability and hemocytometer cell counts.
Vehicle
0.1% DMSO vehicle control.
Reported limits
Salt, lot/purity and the number of independent donor animals contributing to the six separate experiments are not specified in the selected assay description. The single 124.5±3.8% value at 50 µM in Results has no explicit time assignment and is not adopted.
Methods and source locations

Compound reported in the paper: Moclobemide; Compound label in the paper: MB

Evidence concerns the named compound and reported source material; it does not validate Adooq material, purity or a lot.

Methods: isolation/culture, chemicals, cell viability; Results: MB modulates cell viability; Figure 1g–h and caption

MTT signal relative to untreated control across tested exposure times: MTT absorbance at 560 nm; Figure 1g reports mean ± SD of six separate experiments. Exact time-specific values at 50 µM are not extracted from curves. — Figure 1g and caption; Results, MB modulates cell viability

MTT viability at 400 µM relative to no-MB control: MTT; mean ± SD, six separate experiments per Figure 1g caption. Values transcribed from Results text, not estimated from the graph. — Results, MB modulates cell viability, 400 µM sentence; Figure 1g and caption

Moclobemide In Vivo Studies

In male rats, acute moclobemide at 3 or 16 mg/kg intraperitoneally reduced trials to criterion in spatial reversal learning. The 16 mg/kg dose also reduced the proportion of perseverative errors and prolonged initiation of a new trial after an incorrect response. These task-specific effects were measured 1 h after dosing. [3]

Acute moclobemide in rat spatial reversal learning

Animal study · Male Lister-hooded rats trained on spatial-discrimination serial reversal learning; repeated within-subject treatment sessions with randomized modified Latin square order. [3]

Both 3 and 16 mg/kg moclobemide reduced total trials and total errors to criterion versus vehicle. Only 16 mg/kg significantly reduced the proportion of perseverative errors; it also prolonged initiation latency after an incorrect response. Correct-response latency was not significantly altered in the moclobemide cohort. Combination treatment was a separate condition and is not evidence for moclobemide monotherapy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Total trials to reversal-learning criterion versus vehicleReported post hoc significance 16 mg/kg: P<0.001; 3 mg/kg: P<0.0001; combination: P<0.002, respectively as high-dose, low-dose and combination comparisons in Results.[3]
Proportion of perseverative errors, 16 mg/kg versus vehiclePost hoc P value P=0.003; decrease at 16 mg/kg.[3]
Latency to initiate the next trial after an incorrect or correct responseReported comparisons 16 mg/kg prolonged incorrect-response latency versus vehicle (P=0.004); correct-response latency in moclobemide cohort: no significant difference (P=0.105, main effect).[3]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
One injection per test session; treatments in randomized order separated by 3-day intervals.
Treatment course
Acute test session 1 h after injection.
Vehicle
15% hydroxypropyl-beta-cyclodextrin in 0.9% saline.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle
Vehicle only
Within-subject vehicle treatment.Reference condition for the moclobemide treatment comparisons.[3]
Moclobemide 3 mg/kgWithin-subject vehicle treatment.Reduced total trials and errors; no reported significant reduction in the proportion of perseverative errors.[3]
Moclobemide 16 mg/kgWithin-subject vehicle treatment.Reduced total trials, total errors and proportion of perseverative errors; prolonged incorrect-response initiation latency.[3]
Moclobemide plus lazabemide
10 mg/kg moclobemide + 10 mg/kg lazabemide
Within-subject vehicle treatment.Reduced total trials and errors versus vehicle; combination-specific effect. No reported significant reduction of perseverative-error proportion in the moclobemide cohort.[3]
Vehicle
Model: Male Lister-hooded rats in the moclobemide reversal-learning cohort.
Reported limits: No exact bar-height values extracted; n=18 in Figure 4 and n=16 in Figure 5 for this cohort.
Moclobemide 3 mg/kg
Model: Male Lister-hooded rats in the moclobemide reversal-learning cohort.
Reported limits: No exact bar-height values extracted; n=18 in Figure 4 and n=16 in Figure 5 for this cohort.
Moclobemide 16 mg/kg
Model: Male Lister-hooded rats in the moclobemide reversal-learning cohort.
Reported limits: No exact bar-height values extracted; n=18 in Figure 4 and n=16 in Figure 5 for this cohort.
Moclobemide plus lazabemide
Model: Male Lister-hooded rats in the moclobemide reversal-learning cohort.
Reported limits: No exact bar-height values extracted; n=18 in Figure 4 and n=16 in Figure 5 for this cohort.
Methods and source locations

Compound reported in the paper: Moclobemide; Compound label in the paper: moclobemide

Evidence concerns the named compound and reported source material; it does not validate Adooq material, purity or a lot.

Methods: subjects, task, systemic drug administration, statistics; Table 2; Results on reversal learning and response latency; Figures 4–5 and captions

Total trials to reversal-learning criterion versus vehicle: Repeated-measures analysis followed by Fisher LSD comparisons. Figure 4 reports mean ± SEM and n=18 for the moclobemide cohort. Bar heights not digitized. — Results, MAO-A inhibition but not MAO-B inhibition improves reversal learning, first paragraph; Figure 4a caption

Proportion of perseverative errors, 16 mg/kg versus vehicle: Repeated-measures analysis; Figure 4c. Low dose and combination are not reported as significant for this endpoint. — Results, MAO-A inhibition but not MAO-B inhibition improves reversal learning, final paragraph; Figure 4c

Latency to initiate the next trial after an incorrect or correct response: Figure 5 reports mean ± SEM and n=16 for moclobemide; its caption reports technical loss of latency data. No exact seconds estimated. — Results, MAO-A inhibition increases the latency to initiate a new trial following an incorrect response; Figure 5a,c and caption

Vehicle · Methods, Systemic drug administration; Figures 4a,c and 5a,c; associated Results

Moclobemide 3 mg/kg · Methods, Systemic drug administration; Figures 4a,c and 5a,c; associated Results

Moclobemide 16 mg/kg · Methods, Systemic drug administration; Figures 4a,c and 5a,c; associated Results

Moclobemide plus lazabemide · Methods, Systemic drug administration; Figures 4a,c and 5a,c; associated Results

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 71320-77-9
Applications MAO Inhibitor
Formula C13H17ClN2O2
Molecular Weight 268.74
Synonyms Aurorix; Manerix
SMILES
C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 52 mg/mL (193.49 mM)
Water Insoluble
Ethanol 10 mg/mL (37.21 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Moclobemide Research References

  1. [1] Sağlık BN, Cebeci O, Acar Çevik U, et al. Design, Synthesis, In Vitro and In Silico Studies of New Thiazolylhydrazine-Piperazine Derivatives as Selective MAO-A Inhibitors Molecules (Basel, Switzerland) (2020). PMID: 32971892 DOI: 10.3390/molecules25184342 Source material
  2. [2] Chiou SH, Ku HH, Tsai TH, et al. Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway British journal of pharmacology (2006). PMID: 16702990 DOI: 10.1038/sj.bjp.0706766 Source material
  3. [3] Zhukovsky P, Alsiö J, Jupp B, et al. Perseveration in a spatial-discrimination serial reversal learning task is differentially affected by MAO-A and MAO-B inhibition and associated with reduced anxiety and peripheral serotonin levels Psychopharmacology (2017). PMID: 28251298 DOI: 10.1007/s00213-017-4569-x Source material

Publications

1 publication citing this product

  1. Linyu Cao, .et al. , Eur J Pharmacol, 2020, Jun 5;876:173058 PMID: 32131022

Added to your cart

View Cart Checkout
Loading...